Leuprolide Completed Phase 3 Trials for Puberty, Precocious Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00635817A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
NCT00660010Study of Lupron Depot In The Treatment of Central Precocious Puberty